Published on

Medicine – Von Willebrand Disease (VWD)

Von Willebrand disease (VWD) is the most common inherited bleeding disorder. It is caused by a quantitative deficiency or qualitative dysfunction of von Willebrand factor (VWF), resulting in defective platelet adhesion and, in some patients, reduced factor VIII activity.

Important Clinical Principle

Von Willebrand disease primarily causes a platelet-type mucocutaneous bleeding disorder, including easy bruising, epistaxis, menorrhagia and prolonged bleeding from cuts. Severe VWD may also cause deep tissue bleeding because VWF normally stabilises factor VIII.

1. Genetics and Classification

  • The VWF gene is located on chromosome 12.
  • Most cases are inherited in an autosomal dominant pattern.
  • Type 3 VWD is usually autosomal recessive.
  • Some type 2 variants also have autosomal recessive inheritance.
  • VWD affects both males and females.
  • Type 1 is the most common subtype.

Classification of Von Willebrand Disease

Type Defect Inheritance Severity
Type 1 Partial quantitative deficiency of VWF Usually AD Usually mild to moderate
Type 2 Qualitative dysfunction of VWF Usually AD; some AR Variable
Type 3 Virtually complete deficiency of VWF Usually AR Severe

Type 2 Subtypes

  • Type 2A: Reduced platelet-dependent VWF activity, often due to loss of high-molecular-weight multimers.
  • Type 2B: Increased affinity of VWF for platelet GPIb, sometimes causing thrombocytopenia.
  • Type 2M: Reduced platelet-dependent VWF activity without substantial loss of high-molecular-weight multimers.
  • Type 2N: Reduced binding of VWF to factor VIII, potentially mimicking haemophilia A.

2. Pathophysiology

Von Willebrand factor is produced by endothelial cells and megakaryocytes. It is stored in endothelial Weibel–Palade bodies and platelet alpha granules.

VWF has two major physiological functions:

  1. Platelet adhesion: VWF connects exposed subendothelial collagen to platelet glycoprotein Ib (GPIb), allowing platelets to adhere at sites of vascular injury.
  2. Factor VIII stabilisation: VWF binds circulating factor VIII and protects it from rapid clearance.

Illustration: Functions of VWF

Von Willebrand Factor VWF Platelet Adhesion Collagen – VWF – GPIb Factor VIII Protection Stabilises circulating FVIII Defective Adhesion Mucocutaneous bleeding Epistaxis, menorrhagia Reduced Factor VIII Possible prolonged aPTT Severe disease: deep bleeding Defective Primary Haemostasis

Illustration: Platelet Adhesion at a Damaged Vessel

Exposed Subendothelial Collagen Platelet GPIb receptor VWF Bridge Normal Platelet Adhesion

VWF acts as a molecular bridge between platelet GPIb receptors and exposed subendothelial collagen.

3. Clinical Features

Von Willebrand disease typically produces superficial and mucocutaneous bleeding.

  • Easy bruising.
  • Superficial purpura.
  • Recurrent epistaxis (nosebleeds).
  • Gingival bleeding.
  • Heavy menstrual bleeding (menorrhagia).
  • Prolonged bleeding from minor cuts.
  • Excessive bleeding following dental extraction or surgery.
  • Postpartum haemorrhage.

Severe type 3 VWD may cause haemarthroses and deep tissue bleeding due to markedly reduced factor VIII activity.

Examination Point: Mucocutaneous bleeding is characteristic of platelet-type disorders such as VWD, whereas haemophilia more commonly causes haemarthroses and deep muscle bleeding.

4. Laboratory Findings

Investigation Typical Finding
Platelet countUsually normal; may be reduced in type 2B
PT / INRNormal
aPTTNormal or prolonged
VWF antigen (VWF:Ag)Reduced in quantitative deficiency; may be normal in type 2
VWF platelet-binding activityOften reduced, depending on subtype
Factor VIII activity (FVIII:C)Normal or reduced
Ristocetin-induced platelet agglutinationMay be reduced; increased at low ristocetin concentrations in type 2B
Bleeding timeHistorically prolonged; no longer recommended routinely
Important Clarification: Low factor VIII, low VWF antigen and prolonged aPTT are not universal findings. Mild type 1 disease may have a normal aPTT, while type 2 disease may have normal VWF antigen despite impaired VWF function.

5. Diagnosis

Diagnosis combines a personal and family bleeding history with laboratory investigations.

The principal investigations include:

  1. VWF antigen: Measures the amount of VWF in plasma.
  2. VWF activity: Evaluates VWF function, often using platelet-binding assays.
  3. Factor VIII activity: Assesses the effect of VWF on circulating factor VIII.
  4. Specialised subtype testing: May include VWF multimer analysis, collagen-binding assays, factor VIII-binding studies and ristocetin-induced platelet agglutination.

VWF levels may increase during stress, inflammation, pregnancy and other physiological states. Repeat testing may therefore be necessary.

Diagnostic Flowchart

Suspected VWD Mucocutaneous bleeding / family history Initial Investigations CBC, platelet count, PT and aPTT Specific VWF Testing VWF antigen VWF activity + Factor VIII Subtype Assessment Multimers / binding assays / RIPA Repeat testing if indicated Confirm Type and Severity Plan appropriate treatment

6. Treatment of Von Willebrand Disease

Treatment depends on the VWD subtype, bleeding severity, response to desmopressin and the procedure being undertaken.

Treatment Main Indication
Desmopressin (DDAVP)Selected patients, particularly responsive type 1 VWD
VWF-containing concentrateSevere disease, major bleeding, major surgery or inadequate response to DDAVP
Tranexamic acidMucosal bleeding, dental procedures and heavy menstrual bleeding
Hormonal therapyManagement of heavy menstrual bleeding when appropriate

A. Desmopressin (DDAVP)

Desmopressin stimulates the release of stored VWF and factor VIII from endothelial cells.

  • Most useful in responsive type 1 VWD.
  • A supervised desmopressin trial may be required to confirm effectiveness.
  • Can be used for selected minor bleeding episodes or procedures.
  • May cause fluid retention and hyponatraemia.
  • Fluid restriction and appropriate sodium monitoring are important.
  • Generally contraindicated in type 2B VWD because it may worsen thrombocytopenia.
  • Ineffective in type 3 VWD.

B. VWF-Containing Concentrate

VWF replacement is indicated when desmopressin is ineffective, contraindicated or insufficient.

It is particularly important in severe VWD, major bleeding and major surgery.

C. Adjunctive Treatment

  • Tranexamic acid for mucosal bleeding.
  • Appropriate hormonal management for heavy menstrual bleeding.
  • Iron replacement when iron deficiency is present.
  • Individualised management during pregnancy, delivery and the postpartum period.

7. Von Willebrand Disease Versus Haemophilia

Feature VWD Haemophilia A/B
InheritanceUsually autosomal dominantX-linked recessive
Main defectVWF deficiency or dysfunctionFactor VIII or IX deficiency
Bleeding patternMucocutaneous bleedingDeep tissue and joint bleeding
Platelet countUsually normalNormal
PTNormalNormal
aPTTNormal or prolongedOften prolonged
TreatmentDDAVP, VWF concentrate, antifibrinolyticsFactor replacement or other haemophilia-directed therapy

8. High-Yield Examination Summary

Aspect Important Point
DefinitionQuantitative or qualitative abnormality of VWF
GeneticsChromosome 12; usually AD
Most common typeType 1
VWF functionsPlatelet adhesion and factor VIII stabilisation
Clinical presentationEpistaxis, menorrhagia, bruising, mucosal bleeding
PTNormal
aPTTNormal or prolonged
DiagnosisVWF antigen, VWF activity, factor VIII activity
TreatmentDDAVP if responsive; VWF concentrate when indicated

9. Key Examination Pearls

  • VWD is the most common inherited bleeding disorder.
  • The VWF gene is located on chromosome 12.
  • Type 1 is usually autosomal dominant and is the most common subtype.
  • VWF mediates platelet adhesion to exposed subendothelial collagen.
  • VWF also stabilises factor VIII.
  • Clinical manifestations are predominantly mucocutaneous bleeding, including epistaxis and menorrhagia.
  • PT and platelet count are usually normal; aPTT may be normal or prolonged.
  • Diagnosis relies on VWF antigen, VWF activity and factor VIII assays.
  • Desmopressin is useful in selected responsive patients.
  • VWF concentrate is used when replacement is required.
  • Desmopressin should generally be avoided in type 2B and is ineffective in type 3.
Most Important Examination Point

Von Willebrand disease causes defective platelet adhesion and may reduce factor VIII activity. This explains why patients typically experience mucocutaneous bleeding, while severe disease may also produce deeper bleeding resembling haemophilia.

Clinical Note

Von Willebrand disease requires subtype-specific evaluation and treatment. Desmopressin responsiveness, bleeding severity, procedure-related risk and potential adverse effects should be assessed by the treating clinical team. Bleeding time is an outdated investigation and is not recommended for routine diagnosis.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments